Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented history of HZ. Participants (stratified by age: 50–59, 60...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Hum Vaccin Immunother
Glavni autori: Godeaux, Olivier, Kovac, Martina, Shu, Daniel, Grupping, Katrijn, Campora, Laura, Douha, Martine, Heineman, Thomas C., Lal, Himal
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2017
Teme:
Research Papers
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5443374/
https://ncbi.nlm.nih.gov/pubmed/28068212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1265715
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items